Details for New Drug Application (NDA): 217729
✉ Email this page to a colleague
NDA 217729 describes BOSULIF, which is a drug marketed by Pf Prism Cv and is included in two NDAs. It is available from two suppliers. There are four patents protecting this drug and two Paragraph IV challenges. Additional details are available on the BOSULIF profile page.
The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bosutinib monohydrate profile page.
The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bosutinib monohydrate profile page.
Summary for 217729
| Tradename: | BOSULIF |
| Applicant: | Pf Prism Cv |
| Ingredient: | bosutinib monohydrate |
| Patents: | 4 |
Pharmacology for NDA: 217729
| Mechanism of Action | Bcr-Abl Tyrosine Kinase Inhibitors |
Suppliers and Packaging for NDA: 217729
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729 | NDA | Pfizer Laboratories Div Pfizer Inc | 0069-0504 | 0069-0504-30 | 30 CAPSULE in 1 BOTTLE (0069-0504-30) |
| BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729 | NDA | Pfizer Laboratories Div Pfizer Inc | 0069-1014 | 0069-1014-15 | 150 CAPSULE in 1 BOTTLE (0069-1014-15) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 50MG BASE | ||||
| Approval Date: | Sep 26, 2023 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Sep 26, 2026 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
| Regulatory Exclusivity Expiration: | Mar 26, 2027 | ||||||||
| Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
| Regulatory Exclusivity Expiration: | Mar 26, 2031 | ||||||||
| Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
Complete Access Available with Subscription
